Gabor my view is that JELIS offers only a loose guide to what to expect in R-IT
I used the LDL levels and sub optimal use of low intensity Statins in JELIS as example of why I expect there to be moderate at best relevance to R-IT ...where we know that patients will be on optimal Statin dose and as a result their LDL levels will be at least half those in JELIS 2ndry .
Reduce It population on optimal dose Statins is also likely to have lower HsCrp levels ....LDL is only one part of it.
JELIS 2ndry is the closest to R-IT we have for guidance . I-IT trial has IMHO little relevance
I would note this tho from NEJM ( reading from different screen so can't link )...re the Improve It trial
" The extent of benefit afforded by the simavastatin -ezetimbe combination is consistent with that seen in previous statin trials , with a similar reduction in cardiovascular events according to the degree of LDL cholesterol lowering " ( hope you don't mind if I do a "Gabor "...highlight in red ...:-)
So if NEJM is to believed ...the event rate in JELIS would have been lower in both arms if both arms had been on optimal Statin dose . Since they weren't, the JELIS 2ndry data is IMHO only a loose guide.
JMO
Kiwi
Market Data 
Markets 
AI
